Similar dynamics are suggested in ALS.40 NfL levels in CSF and, according to our data, likely also in serum may thus serve as a biomarker for an active disease process coinciding with the onset of clinical symptoms in genetic FTD. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.